Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company wholesales medications and medical consumables.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 34.8% | 31.3% | 30.2% | 31.4% | 31.7% | 36.1% | 34.6% |
| EBITDA Margin | 20.5% | 16.4% | 20.6% | 23.6% | 20.4% | 25.7% | 25.4% |
| EBITDAR | 533 | 441 | 742 | 1,120 | 1,083 | 1,187 | 1,443 |
| EBITDAR Margin | 22.6% | 18.6% | 22.2% | 24.9% | 22.3% | 27.5% | 26.6% |
| EBIT Margin | 20.3% | 16.1% | 20.4% | 23.5% | 20.2% | 25.6% | 25.3% |
| Net Profit Margin | 19.3% | 11.4% | 15.6% | 23.5% | 20.8% | 24.3% | 23.5% |
| Operating Expense % of Sales | 14.3% | 14.9% | 9.6% | 7.8% | 11.3% | 10.4% | 9.2% |
| Returns | |||||||
| Return on Assets (ROA) | 20.5% | 14.1% | 23.1% | 33.9% | 26.7% | 25.5% | 25.6% |
| Return on Equity (ROE) | 21.5% | 14.5% | 46.7% | 48.6% | 31.8% | 27.2% | 26.8% |
| ROIC [EBIT / Invested Capital] | 25.5% | 21.4% | 36.1% | 41.1% | 31.4% | 29.0% | 29.2% |
| Leverage & debt balances | |||||||
| Debt-to-Assets | 0.0% | 0.0% | 35.2% | 14.8% | 0.8% | 0.1% | 0.1% |
| Debt-to-Equity | 0.00x | 0.00x | 0.71x | 0.21x | 0.01x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 1.16x | 0.44x | 0.03x | 0.00x | 0.00x |
| Equity-to-Assets | 95.5% | 97.3% | 49.4% | 69.7% | 84.1% | 93.5% | 95.6% |
| Net Debt | -247 | -87 | 770 | 392 | -58 | -40 | -64 |
| Cash & Equivalents | 247 | 87 | 28 | 71 | 88 | 44 | 69 |
| Total Debt | N/A | N/A | 797 | 463 | 31 | 4 | 4 |
| Liquidity & working capital | |||||||
| Current Ratio | 25.10x | 35.30x | 6.37x | 6.35x | 6.52x | 15.44x | 22.91x |
| Quick Ratio | 25.10x | 18.00x | 3.77x | 6.35x | 6.52x | 15.44x | 22.91x |
| Cash Ratio | 2.87x | 1.66x | 0.08x | 0.15x | 0.16x | 0.17x | 0.32x |
| Total Current Assets | 2,158 | 1,851 | 2,216 | 3,055 | 3,716 | 4,066 | 4,945 |
| Total Current Liabilities | 86 | 52 | 348 | 481 | 570 | 263 | 216 |
| Inventory | N/A | 907 | 904 | N/A | N/A | N/A | N/A |
| Trade Receivables | 1,221 | 856 | 1,273 | 1,747 | 2,302 | 2,588 | 2,838 |
| Trade Payables | 98 | 44 | 345 | 480 | 570 | 263 | 208 |
| Net Working Capital | 2,072 | 1,799 | 1,868 | 2,574 | 3,146 | 3,802 | 4,729 |
| Net Working Capital % of Revenue | 87.7% | 75.8% | 56.0% | 57.3% | 64.8% | 88.2% | 87.2% |
| Trade Working Capital | 1,123 | 1,719 | 1,832 | 1,267 | 1,732 | 2,325 | 2,631 |
| Trade Working Capital % of Revenue | 47.6% | 72.5% | 54.9% | 28.2% | 35.7% | 53.9% | 48.5% |
| Change in Trade Working Capital | N/A | 595 | 114 | -565 | 465 | 593 | 306 |
| Turnover & efficiency | |||||||
| Inventory Turnover | N/A | 1.80x | 2.58x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 203.3 | 141.6 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 1.93x | 2.77x | 2.62x | 2.57x | 2.11x | 1.67x | 1.91x |
| Days Sales Outstanding (DSO) | 188.7 | 131.7 | 139.2 | 142.0 | 173.1 | 219.1 | 191.0 |
| Payables Turnover | 15.74x | 36.76x | 6.76x | 6.42x | 5.82x | 10.47x | 17.09x |
| Days Payable Outstanding (DPO) | 23.2 | 9.9 | 54.0 | 56.8 | 62.7 | 34.9 | 21.4 |
| Cash Conversion Cycle | 165.5 days | 325.1 days | 226.9 days | 85.1 days | 110.4 days | 184.2 days | 169.7 days |
| Asset Turnover | 1.06x | 1.23x | 1.47x | 1.44x | 1.28x | 1.05x | 1.09x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →